Biogen to acquire rare inherited retinal disease drug developer

4 March 2019
biogen-big-1

The growing interest in gene therapies was further confirmed by US Biotech major Biogen (Nasdaq: BIIB), which has reached an agreement to acquire a UK-based clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, at a price of $25.50 per share in cash.

The offer values Nightstar Therapeutics (Nasdaq: NITE), a company formed six years ago by Syncona, at $877 million, which represents a 4.5x multiple on Syncona's original investment of £56.4 million and an internal rate of return (IRR) of 72%. The sale of Nightstar will generate £254.6 million of proceeds for Syncona.

Nightstar’s US traded shares soared 66.42% to $25.23 in pre-market trading today.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology